Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could exercise reshape gut bacteria in fatty liver disease?

NCT ID NCT07697313

Disease control Sponsor: Horus University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This trial investigates whether high-intensity interval training or moderate continuous exercise, combined with a Mediterranean diet, can improve gut bacteria and metabolic health in people with non-alcoholic fatty liver disease. Participants are adults aged 40-60 with obesity and fatty liver who have not exercised regularly. The study measures changes in gut short-chain fatty acids, blood lipids, and quality of life over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
exercise training (high-intensity interval training or moderate intensity continuous training) plus Mediterranean diet
What this could lead to
If successful, this could show that a specific exercise program improves gut bacteria and metabolic health in people with fatty liver, offering a drug-free way to manage the condition.
What could go wrong
This is a small, early-stage trial with 60 participants, so results may not apply to everyone. The effects on gut microbiota are measured indirectly and may not translate to clear health benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients from both genders aged 40 - 60 years old diagnosed with Non-alcoholic Fatty Liver disease by ultrasonography. 2. Body mass index will range from 30 to 34.9 kg/m². 3. Patients with central obesity (waist circumference 90 cm for men and 85 cm for women). 4. Patients who have taken no regular exercise in the last year (\<3 times/week and 30 min/time. 5. No antibiotic or probiotic use for at least last 3 months. 6. Medical drugs such as metformin, sulfonylureas, statins, and blood pressure medication were eligible, as well as stable. Exclusion Criteria: 1. History of liver cirrhosis or other chronic liver diseases. 2. Use of medications affecting gut microbiota (e.g., laxatives, metformin, proton pump inhibitors). 3. Recent gastrointestinal infections or surgeries. 4. Diabetes Mellitus type 1 or uncontrolled type 2. 5. Cardiovascular, respiratory, or musculoskeletal disorders limiting exercise capacity. 6. Active smokers. 7. Pregnancy or breastfeeding. 8. Uncontrolled hypertension. 9. Communication disorders. 10. Bleeding disorders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non alcoholic fatty liver are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non alcoholic fatty liver

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • out-patient clinic, faculty of physical therapy, Horus university

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.